Endothelin-1(1-31) levels are increased in atherosclerotic lesions of the thoracic aorta of hypercholesterolemic hamsters

Atherosclerosis

Volumn 175, Issue 2, 2004, Pages 203-212

  Mawatari, Kazuaki ^a,b   Kakui, Sae ^a   Harada, Nagakatsu ^a   Ohnishi, Takamasa ^a   Niwa, Yasuharu ^a   Okada, Kazuko ^a   Takahashi, Akira ^a   Izumi, Keisuke ^a   Nakaya, Yutaka ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b NAGASAKI INTERNATIONAL UNIVERSITY   (Japan)

Author keywords

Atherosclerosis; Endothelin; Hamster; Hypercholesterolemia; Nitric oxide

Indexed keywords

CHOLESTEROL; ENDOTHELIN 1; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE INHIBITOR;

ADVENTITIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL DIET; CONTROLLED STUDY; DISEASE SEVERITY; HAMSTER; HYPERCHOLESTEROLEMIA; INFLAMMATION; INTIMA; MALE; MAST CELL; NONHUMAN; PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; THORACIC AORTA; VASOCONSTRICTION;

ANIMALS; AORTA, THORACIC; ARTERIOSCLEROSIS; BLOOD PRESSURE; CHOLESTEROL; CRICETINAE; DISEASE MODELS, ANIMAL; ENDOTHELIN-1; HEART RATE; HYPERCHOLESTEROLEMIA; MALE; PEPTIDE FRAGMENTS; TRIGLYCERIDES; VASOCONSTRICTION;

EID: 3242659977     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2003.10.015     Document Type: Article

References (30)

1. Xu D., Emoto N., Giaid A., Slaughter C., Kaw S., deWit D., et al. ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell. 78:1994;473-485
2. Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 322:1988;411-415
3. Haynes W.G., Webb D.J. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet. 344:1994;852-854
4. Lerman A., Edwards B.S., Hallet J.W., Heublein D.M., Sandberg S.M., Burnett J.C. Jr. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N. Engl. J. Med. 325:1991;997-1001
5. Winkles J.A., Alberts G.F., Brogi E., Libby P. Endothelin-1 and endothelin receptor mRNA expression in normal and atherosclerotic human arteries. Biochem. Biophys. Res. Commun. 191:1993;1081-1088
6. Nakano A., Kishi F., Minami K., Wakabayashi H., Nakaya Y., Kido H. Selective conversion of big endothelins to tracheal smooth muscle-constricting 31-amino acid-length endothelins by chymase from human mast cells. J. Immunol. 159:1997;1987-1992
7. Kishi F., Minami K., Okishima N., Murakami M., Mori S., Yano M., et al. Novel 31-amino-acid-length endothelin cause constriction of vascular smooth muscle. Biochem. Biophys. Res. Commun. 248:1998;387-390
8. Nagata N., Niwa Y., Nakaya Y. A novel 31-amino-acid-length endothelin, ET-1(1-31), can act as a biologically active peptide for vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 275:2000;595-600
9. Shiota N., Fukamizu A., Takai S., Okunishi H., Murakami K., Miyazaki M. Activation of angiotensin II-forming chymase in the cardiomyopathic hamster heart. J. Hypertens. 15:1997;431-440
10. Bocan T.M. Animal models of atherosclerosis and interpretation of drug intervention studies. Curr. Pharm. Des. 4:1998;37-52
11. Kowala M.C., Rose P.M., Stein P.D., Goller P.D., Recce R., Beyer S., et al. Selective blockade of the endothelin subtype A receptor decrease early atherosclerosis in hamster fed cholesterol. Am. J. Pathol. 146:1995;819-826
12. Böger R.H., Bode-Böger S.M., Frölich J.C. The L-arginine-nitric oxide pathway: role in atherosclerosis and therapeutic implications. Atherosclerosis. 127:1996;1-11
13. Wennmalm A. Nitric oxide in the cardiovascular system: role in atherosclerosis and hypercholesterolemia. Blood Press. 3:1994;279-282
14. Stary H.C., Chandler A.B., Glagov S., Guyton J.R., Insull W. Jr., Rosenfeld M.E., et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 89:1994;2462-2478
15. Fuster V.L. A Cornner Memorial Lecture. Mechanism leading myocardial infarction: insights from studies of vascular biology. Circulation. 90:1994;2126-2146
16. 2 dose not contribute to impaired endothelium-dependent relaxation. Arterioscler. Thromb. 14:1994;746-752
17. Cayatte A.J., Palacino J.J., Horten K., Cohen R.A. Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits. Arterioscler. Thromb. 12:1994;753-759
18. Nakamura M., Abe S., Tanaka M. Oral administration of NO synthase inhibitor failed to promote arteriosclerosis lesion on aorta and coronary arteries of rabbits fed cholesterol. Atherosclerosis. 141:1998;53-60
19. Böger R.H., Bode-Böger S.M., Kienke S., Stan A.C., Nafe R., Förlich J.C. Dietary L-arginine decreases myointimal cell proliferation and vascular myocyte accumulation in cholesterol-fed rabbits. Atherosclerosis. 136:1998;67-77
20. Radomski M.W., Palmer R.M.J., Moncada S. Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin on platelets. Br. J. Pharmacol. 92:1987;181-187
21. Bath P.M., Hassall D.G., Gladwin A.M., Palmer R.M.J., Martin J.F. Nitric oxide and prostacyclin: divergence of inhibitory effects on monocyte chemotaxis and adhesion to endothelium in vitro. Arterioscler. Thromb. 11:1991;254-260
22. Garg U.C., Hassid S. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J. Clin. Invest. 83:1989;1774-1777
23. Böger R.H., Bode-Böger S.M., Kienke S., Stan A.C., Nafe R., Förlich J.C. Dietary L-arginine decreases myointimal cell proliferation and vascular myocyte accumulation in cholesterol-fed rabbits. Atherosclerosis. 136:1998;67-77
24. ω-L-nitro-arginine methyl ester on renal function and blood pressure. Am. J. Physiol. 261:1991;F1033-F1037
25. Maguire J.J., Kuc R.E., Davenport A.P. Affinity and selectivity of PD156707, a novel non-peptide endothelin antagonist, for human ETA and ETB receptors. J. Pharmacol. Exp. Ther. 280:1997;1102-1108
26. Pernow J., Böhm F., Jahansson B.L., Hedin U., Ryuden L. Enhanced vasoconstrictor response to endothelin-B-receptor stimulation in patients with atherosclerosis. J. Cardiovasc. Pharmacol. 36:2000;S418-S420
27. Okishima N., Hagiwara Y., Seito T., Yano M., Kido H. Specific sandwich-type enzyme immunoassays for smooth muscle constricting novel 31-amino acid endothelins. Biochem. Biophys. Res. Commun. 256:1999;1-5
28. Cui P., Tani K., Kitamura H., Okumura Y., Yano M., Inui D., et al. A novel bioactive 31-amino acid endothelin-1 is potent chemotactic peptide for human neutrophils and monocytes. J. Leukoc. Biol. 70:2001;306-312
29. Sharmin S., Shiota M., Murata E., Cui P., Kitamura H., Yano M., et al. A novel bioactive 31-amino acid endothelin-1 peptide stimulates eosinophil recruitment, and increased level of eotaxin and IL-5. Inflamm. Res. 51:2002;195-200
30. Ross R. Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 340:1999;115-126